eFFECTOR Therapeutics Gets $45M For Cancer Treatments

San Diego-based eFFECTOR Therapeutics said today that it has raised $45M to go towards the development and invention of small molecule drugs, specifically aimed at treating cancer. According to the firm, the Series A investment included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital. eFFECTOR said the new funds will go towards multiple discovery programs, plus acquisition of data on patients for its lead drug candidate. The firm's founding team comes from the University of California San Francisco. More information »